Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.15 HKD | -0.99% | +2.90% | -22.89% |
Apr. 29 | China, HK stocks rise, led by property shares | RE |
Apr. 11 | China stocks rise as commodities shine; Hong Kong snaps winning streak | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 55% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- With an expected P/E ratio at 40.98 and 31.35 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.89% | 12.43B | B | ||
-24.53% | 6.57B | B | ||
+15.41% | 6.46B | C | ||
-10.73% | 6.04B | C+ | ||
-3.21% | 4.63B | D- | ||
+60.00% | 4.61B | C | ||
-6.67% | 3.94B | B | ||
-10.60% | 3.51B | C- | ||
-6.00% | 3.04B | C- | ||
-8.66% | 2.62B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6618 Stock
- Ratings JD Health International Inc.